Superior execution and lower RM costs drive earnings

Company
06 Aug 2024
5 Min read 
  • GSK Pharma's 1QFY25 results update and financials 
  •  Estimate, TP, and rating change 
  •  Sales, EBITDA, and Adj. PAT growth 
  •  Valuations and shareholding pattern 
  •  Strong demand in specialty portfolio 
  •  Plans for operational efficiency and new products 
  •  Reiterate Neutral with 9% earnings CAGR.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority

Click here to see your activities